[go: up one dir, main page]

WO2007074169A3 - Compositions and methods for the inhibition of phospholipase a2 - Google Patents

Compositions and methods for the inhibition of phospholipase a2 Download PDF

Info

Publication number
WO2007074169A3
WO2007074169A3 PCT/EP2006/070256 EP2006070256W WO2007074169A3 WO 2007074169 A3 WO2007074169 A3 WO 2007074169A3 EP 2006070256 W EP2006070256 W EP 2006070256W WO 2007074169 A3 WO2007074169 A3 WO 2007074169A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
phospholipase
inhibition
compositions
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/070256
Other languages
French (fr)
Other versions
WO2007074169A2 (en
Inventor
Guichard Gilles
Lena Gersande
Pascal Muller
Didier Rognang
Gerard Lambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmuPharma France SA
Original Assignee
ImmuPharma France SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmuPharma France SA filed Critical ImmuPharma France SA
Priority to JP2008547973A priority Critical patent/JP2009522234A/en
Priority to CA2635354A priority patent/CA2635354C/en
Priority to EP06830846A priority patent/EP1966169A2/en
Priority to AU2006331355A priority patent/AU2006331355B2/en
Publication of WO2007074169A2 publication Critical patent/WO2007074169A2/en
Publication of WO2007074169A3 publication Critical patent/WO2007074169A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.
PCT/EP2006/070256 2005-12-29 2006-12-28 Compositions and methods for the inhibition of phospholipase a2 Ceased WO2007074169A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008547973A JP2009522234A (en) 2005-12-29 2006-12-28 Compositions and methods for inhibiting phospholipase A2
CA2635354A CA2635354C (en) 2005-12-29 2006-12-28 Compositions and methods for the inhibition of phospholipase a2
EP06830846A EP1966169A2 (en) 2005-12-29 2006-12-28 Compositions and methods for the inhibition of phospholipase a2
AU2006331355A AU2006331355B2 (en) 2005-12-29 2006-12-28 Compositions and methods for the inhibition of phospholipase A2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75562605P 2005-12-29 2005-12-29
US60/755,626 2005-12-29

Publications (2)

Publication Number Publication Date
WO2007074169A2 WO2007074169A2 (en) 2007-07-05
WO2007074169A3 true WO2007074169A3 (en) 2007-11-15

Family

ID=38006877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/070256 Ceased WO2007074169A2 (en) 2005-12-29 2006-12-28 Compositions and methods for the inhibition of phospholipase a2

Country Status (6)

Country Link
EP (1) EP1966169A2 (en)
JP (1) JP2009522234A (en)
CN (1) CN101405276A (en)
AU (1) AU2006331355B2 (en)
CA (1) CA2635354C (en)
WO (1) WO2007074169A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033167A1 (en) 2005-12-29 2008-02-07 Gilles Guichard Compositions and methods for synthesizing heterocyclic therapeutic compounds
EP3533460A1 (en) * 2018-03-02 2019-09-04 Diaccurate Therapeutic anti-spla2-gib antibodies and the uses thereof
CN114436983B (en) * 2021-11-23 2023-05-23 辽宁中医药大学 Oleraze and Oleraoxazine acid in purslane and their extraction and separation methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009133A1 (en) * 1991-10-31 1993-05-13 Smithkline Beecham Corporation C8-cyclic peptidomimetics as fibrinogen antagonists
WO2001090083A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
FR2810039A1 (en) * 2000-06-13 2001-12-14 Centre Nat Rech Scient Preparation of new or known cyclic urea compounds for pharmaceutical use, by deprotecting and cyclizing protected amino-substituted activated carbamic acid derivative
WO2002028842A2 (en) * 2000-10-02 2002-04-11 Novartis Ag Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist
WO2003103677A1 (en) * 2002-06-10 2003-12-18 The Procter & Gamble Company Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60123479A (en) * 1983-11-17 1985-07-02 ジ・アツプジヨン・カンパニー 4,1-benzoxazepin-2(3h)-one compound
JPS63501217A (en) * 1985-10-18 1988-05-12 ジ・アップジョン・カンパニ− Cyclic hydrocarbons with aminoalkyl side chains
JP2873340B2 (en) * 1988-04-29 1999-03-24 武田薬品工業株式会社 Antibiotic TAN-1057, its production method and use
CA2395862A1 (en) * 2000-02-17 2001-08-23 Hong Liu Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
JP2005520171A (en) * 2001-04-10 2005-07-07 トランス　テック　ファーマ，インコーポレイテッド Probes, systems, and methods for drug discovery
EP1973887B1 (en) * 2005-12-29 2012-09-19 Immupharma France SA Aza heterocyclics for the treatment of malaria or aids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009133A1 (en) * 1991-10-31 1993-05-13 Smithkline Beecham Corporation C8-cyclic peptidomimetics as fibrinogen antagonists
WO2001090083A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
FR2810039A1 (en) * 2000-06-13 2001-12-14 Centre Nat Rech Scient Preparation of new or known cyclic urea compounds for pharmaceutical use, by deprotecting and cyclizing protected amino-substituted activated carbamic acid derivative
WO2002028842A2 (en) * 2000-10-02 2002-04-11 Novartis Ag Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist
WO2003103677A1 (en) * 2002-06-10 2003-12-18 The Procter & Gamble Company Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOILARD, ERIC ET AL: "Secreted Phospholipase A2 Inhibitors Are Also Potent Blockers of Binding to the M-Type Receptor", BIOCHEMISTRY , 45(44), 13203-13218 CODEN: BICHAW; ISSN: 0006-2960, 2006, XP002451620 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, SEMETEY, VINCENT ET AL: "O-succinimidyl carbamate derivatives from amino acids and peptides: a general entry to urea-based peptidomimetics", XP002451622, retrieved from STN Database accession no. 2003:509438 *
LENA ET AL: "1,3,5-Triazepan-2,6-diones as structurally diverse and conformationally constrained dipeptide mimetics: identification of malaria liver stage inhibitors from a small pilot library", CHEMISTRY - A EUROPEAN JOURNAL, VCH PUBLISHERS, US, vol. 12, no. 33, 15 November 2006 (2006-11-15), pages 8498 - 8512, XP002424879, ISSN: 0947-6539 *
PEPTIDES 2000, PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, 26TH, MONTPELLIER, FRANCE, SEPT. 10-15, 2000 ( 2001 ), MEETING DATE 2000, 161-162. EDITOR(S): MARTINEZ, JEAN; FEHRENTZ, JEAN-ALAIN. PUBLISHER: EDITIONS EDK, PARIS, FR. CODEN: 69EDWK; IS, 2003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists

Also Published As

Publication number Publication date
CN101405276A (en) 2009-04-08
CA2635354A1 (en) 2007-07-05
AU2006331355A1 (en) 2007-07-05
CA2635354C (en) 2012-07-10
AU2006331355A2 (en) 2009-08-13
EP1966169A2 (en) 2008-09-10
JP2009522234A (en) 2009-06-11
AU2006331355B2 (en) 2011-09-29
WO2007074169A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008013838A3 (en) Pyridizinone derivatives
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2009108383A3 (en) Substituted xanthine derivatives
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
WO2008001101A3 (en) Pharmaceutical combinations
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2007146124A3 (en) Deuterated tadalafil derivatives
TNSN08191A1 (en) Kinase inhibitors
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
TW200420541A (en) Crystalline forms
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
WO2007103762A3 (en) Compositions and methods of use of electron transport system inhibitors
NO20080033L (en) Quinoline derivatives as NK3 antagonists
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2008011113A3 (en) Thiadiazolidinone derivatives
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006331355

Country of ref document: AU

Ref document number: 2635354

Country of ref document: CA

Ref document number: 2008547973

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006830846

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5985/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006331355

Country of ref document: AU

Date of ref document: 20061228

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006331355

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06830846

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680053553.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006830846

Country of ref document: EP